My Treatment Approach: Expert Insights Into the Management of Polycythemia Vera : Episode 7

Opinion

Video

September 1, 2023

Managing Toxicities of Hydroxyurea in Patients With PV

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

EP: 1.Risk Assessment in Patients With Polycythemia Vera (PV)

EP: 2.Reducing Risk of Disease Progression in Patients With PV

EP: 3.Typical Presentation of a Patient With PV

EP: 4.Importance of Bone Marrow Biopsy For Diagnosis of PV

EP: 5.Reducing Risk of Thrombosis in Patients With PV

EP: 6.Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

Now Viewing

EP: 7.Managing Toxicities of Hydroxyurea in Patients With PV

EP: 8.Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

EP: 9.Key Trials in the Treatment of PV

EP: 10.Treatment Approaches for High-Risk Patients With PV

EP: 11.Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

EP: 12.Ruxolitinib in the Treatment of PV

EP: 13.Future Perspectives in the Treatment of Polycythemia Vera

Related Content

November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

November 5th 2024

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute

October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis